

Non-GAAP Financial Measures and Reconciliations

We use various numerical measures in this news release, as well as in conference calls, investor meetings and other forums which are or may be considered "Non-GAAP financial measures" under Regulation G. We have provided below for your reference supplemental financial disclosure for these measures, including the most directly comparable GAAP measure and an associated reconciliation.

Kensley Nash Corporation Non-GAAP Financial Measures and Reconciliations Adjusted Earnings Per Share Reconciliation

	Three Months Ended <u>June 30, 2008</u>	Three Months Ended <u>June 30, 2007</u>	Year over Year % Change
Loss Per Share - GAAP	\$ (0.09)	\$ (0.15)	
Special Charges (a)	0.44	0.25	
Adjusted Diluted Earnings Per Share	<u>\$ 0.35</u>	<u>\$ 0.11</u>	<u>218%</u>

(a) Loss per share for the fourth quarter of fiscal year 2008 includes \$8.1 million in net charges (\$5.4 million in after-tax charges, or \$0.44 per share tax-effected), related to the sale of the Company's endovascular business. Loss per share for the fourth quarter of fiscal year 2007 included \$4.7 million in charges (\$3.1 million in after-tax charges, or \$0.25 per share tax-effected), related to the discontinuance of the Company's embolic protection platform.

	Fiscal Year Ended <u>June 30, 2008</u>	Fiscal Year Ended <u>June 30, 2007</u>	Year over Year % Change
Diluted Earnings Per Share - GAAP	\$ 0.38	\$ 0.29	31%
Special Charges (b)	0.61	0.25	
Adjusted Diluted Earnings Per Share	<u>\$ 0.99</u>	<u>\$ 0.53</u>	<u>87%</u>

(b) Diluted earnings per share for fiscal year 2008 includes \$3.0 million in net charges (\$2.0 million in after-tax charges, or \$0.16 per share tax-effected), for the acceleration of stock awards, approximately \$324,000 in charges (\$215,000 in after-tax charges, or \$0.02 per share tax-effected), related to the discontinuation of the Company's embolic protection platform, both of which were incurred during the first quarter of fiscal 2008, and \$8.1 million in net charges (\$5.4 million, or \$0.44 per share tax-effected), related to the sale of the Company's endovascular business during the fourth quarter of fiscal year 2008. Diluted earnings per share for the fourth quarter of fiscal year 2007 included \$4.7 million in charges (\$3.1 million in after-tax charges, or \$0.25 per share tax-effected), related to the discontinuance of the Company's embolic protection platform.

	Three Months Ended <u>September 30, 2008</u>		Three Months Ended <u>September 30, 2007</u>		Year over Year % Change	
	Range				Range	
	Low	High			Low	High
Diluted Earnings Per Share - GAAP	\$ 0.37	\$ 0.38	\$ (0.02)			
Special Charges (c)			0.18			
Adjusted Diluted Earnings Per Share	<u>\$ 0.37</u>	<u>\$ 0.38</u>	<u>\$ 0.16</u>		<u>131%</u>	<u>138%</u>

(c) Diluted earnings per share for the first quarter of fiscal year 2008 included \$3.0 million in charges (\$2.0 million in after-tax charges, or \$0.16 per share tax-effected), for the acceleration of stock awards, and approximately \$324,000 in charges (\$215,000 in after-tax charges, or \$0.02 per share tax-effected), related to the discontinuation of the Company's embolic protection platform.

	Fiscal Year Ended <u>June 30, 2009</u>		Fiscal Year Ended <u>June 30, 2008</u>		Year over Year % Change	
	Range				Range	
	Low	High			Low	High
Diluted Earnings Per Share - GAAP	\$ 1.60	\$ 1.67	\$ 0.38			
Special Charges (d)			0.61			
Adjusted Diluted Earnings Per Share	<u>\$ 1.60</u>	<u>\$ 1.67</u>	<u>\$ 0.99</u>		<u>62%</u>	<u>69%</u>

(d) Diluted earnings per share for fiscal year 2008 included \$3.0 million in charges (\$2.0 million in after-tax charges, or \$0.16 per share tax-effected), for the acceleration of stock awards, approximately \$324,000 in charges (\$215,000 in after-tax charges, or \$0.02 per share tax-effected), related to the discontinuation of the Company's embolic protection platform, and \$8.1 million in net charges (\$5.4 million, or \$0.44 per share tax-effected), related to the sale of the Company's endovascular business during the fourth quarter of fiscal year 2008.

Note: To supplement our consolidated financial statements presented in accordance with GAAP, Kensley Nash Corporation uses non-GAAP measures of adjusted earnings per share, which are adjusted from our GAAP results to exclude certain expenses. These non-GAAP adjustments are provided to enhance the user's overall understanding of our historical and current financial performance and our prospects for the future. We believe the non-GAAP results provide useful information to both management and investors by excluding certain expenses that we believe are not indicative of our core operating results.

These non-GAAP measures will provide investors and management with an alternative method for assessing Kensley Nash's operating results in a manner consistent with future presentation. Further, these non-GAAP results are one of the primary indicators management uses for planning and forecasting in future periods. The presentation of this additional information should not be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.